Academic Journals Database
Disseminating quality controlled scientific knowledge

Role of ofatumumab in treatment of chronic lymphocytic leukemia

ADD TO MY LIST
 
Author(s): Veliz M | Pinilla-Ibarz J

Journal: Journal of Blood Medicine
ISSN 1179-2736

Volume: 2011;
Issue: default;
Start page: 71;
Date: 2011;
Original page

ABSTRACT
Marays Veliz, Javier Pinilla-IbarzH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAAbstract: The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal antibodies to the treatment armamentarium. Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved in the US and Europe for the treatment of CLL refractory to alemtuzumab and fludarabine. Preclinical data showed improved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab. Clinical studies have shown single-agent activity for ofatumumab in CLL and in other low-grade non-Hodgkin's lymphomas. Combination studies are being conducted to enhance the therapeutic efficacy of ofatumumab. This paper reviews some of the key clinical studies that led to approval of ofatumumab, and future directions.Keywords: ofatumumab, chronic lymphocytic leukemia, efficacy, safety

Tango Jona
Tangokurs Rapperswil-Jona

     Save time & money - Smart Internet Solutions